Filed with ASX · · 7 pages · English
The report highlights the progress of the Libbo® pilot clinical study and the operational status of the patient access pathway for its erectile dysfunction oral film. The company reported a closing cash balance at the end of the quarter, with no borrowings, indicating its financial position. EVE Health Group is focused on advancing its reformulation pipeline and preparing for future clinical studies and product registrations.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
ASX ANNOUNCEMENT 30 Oct ober 2026 Quarterly Activities Report For the quarter ended 30 September 2026 QUARTER HIGHLIGHTS — Commercial pathway operating end to end: patient education, telehealth consultation, pharmacy fulfilment and discreet home delivery are now fully operational for the...
EVE Health Group Limited on 6ix
